Table I.
Demographics of 33 patients with osteosarcoma treated with apatinib+IE in the study.
| Variable | Value |
|---|---|
| Age, median years (minimum, maximum) | 16.0 (3.0, 48.0) |
| Age groupa, n (%) | |
| Child | 8 (24.2) |
| Adolescent | 9 (27.3) |
| Adult | 16 (48.5) |
| Sex, n (%) | |
| Male | 14 (42.4) |
| Female | 19 (57.6) |
| ECOG performance status before treatment, n (%) | |
| 0 | 20 (60.6) |
| 1 | 11 (33.3) |
| 2 | 2 (6.1) |
| Sites of target and non-target lesions before treatment, n (%) | |
| Lung only | 13 (39.4) |
| Musculoskeletal sites only | 3 (9.1) |
| Lung + musculoskeletal sites | 16 (48.5) |
| Lung + bone + other sitesb, n (%) | 1 (3.0) |
| Lines of previous chemotherapy including MAP/Ic, n (%) | |
| 1 | 15 (45.4) |
| 2 | 16 (48.5) |
| 3 | 2 (6.1) |
| High-grade osteosarcoma subtypes, n (%) | |
| Canonical (osteoblastic, chondroblastic, fibroblastic) | 32 (97.0) |
| Small cell | 0 (0.0) |
| Telangiectatic | 1 (3.0) |
| Resistance to MAP/I chemotherapyd, n (%) | |
| Yes | 33 (100.0) |
| No | 0 (0.0) |
| Resistance to IE chemotherapye, n (%) | |
| Yes | 12 (36.4) |
| No | 21 (63.6) |
| Resistance to apatinibf, n (%) | |
| Yes | 2 (6.1) |
| No | 31 (93.9) |
Groups defined according to Collins et al (30): Child (0–12 for males and 0-11 years for females), adolescent (13–17 for males and 12-16 years for females) and adult (≥18 for males and ≥17 years for females).
Other sites including lymph nodes, visceral metastasis and/or brain metastasis.
MAP/I, including high-dose methotrexate (12 g/m2), doxorubicin (75 mg/m2), cisplatin (100–120 mg/m2) with or without ifosfamide (12 g/m2).
Resistance to MAP/I chemotherapy based on RECIST 1.1, patients who exhibited disease progression upon MAP/I chemotherapy.
Resistance to IE chemotherapy based on RECIST 1.1, patients who exhibited disease progression upon IE chemotherapy.
Resistance to apatinib based on RECIST 1.1, patients who exhibited disease progression upon single apatinib treatment. ECOG, Eastern Cooperative Oncology Group; IE, ifosfamide and etoposide; MAP/I, high-dose methotrexate, doxorubicin, cisplatin with or without ifosfamide; RECIST, Response Evaluation Criteria for Solid Tumours.